Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

19 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Online Medical Misinformation in Cancer: Distinguishing Fact From Fiction.
Teplinsky E, Ponce SB, Drake EK, Garcia AM, Loeb S, van Londen GJ, Teoh D, Thompson M, Schapira L; Collaboration for Outcomes using Social Media in Oncology (COSMO). Teplinsky E, et al. JCO Oncol Pract. 2022 Aug;18(8):584-589. doi: 10.1200/OP.21.00764. Epub 2022 Mar 31. JCO Oncol Pract. 2022. PMID: 35357887 Free PMC article. Review.
Netiquette for social media engagement for oncology professionals.
Ponce SB, M Barry M, S Dizon D, S Katz M, Murphy M, Teplinsky E, Tinianov S, J Attai D, Markham MJ. Ponce SB, et al. Among authors: teplinsky e. Future Oncol. 2022 Mar;18(9):1133-1141. doi: 10.2217/fon-2021-1366. Epub 2022 Feb 3. Future Oncol. 2022. PMID: 35109663 Free PMC article. Review.
Dobbs v Jackson- Rewriting Women's Autonomy in Cancer Care.
Mittal K, Sheen M, Wheelden M, Faramand R, Teplinsky E, Joshi M. Mittal K, et al. Among authors: teplinsky e. JCO Oncol Pract. 2023 Apr;19(4):157-159. doi: 10.1200/OP.22.00610. Epub 2023 Jan 18. JCO Oncol Pract. 2023. PMID: 36652658 No abstract available.
American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care.
Pennell NA, Dillmon M, Levit LA, Moushey EA, Alva AS, Blau S, Cannon TL, Dickson NR, Diehn M, Gonen M, Gonzalez MM, Hensold JO, Hinyard LJ, King T, Lindsey SC, Magnuson A, Marron J, McAneny BL, McDonnell TM, Mileham KF, Nasso SF, Nowakowski GS, Oettel KR, Patel MI, Patt DA, Perlmutter J, Pickard TA, Rodriguez G, Rosenberg AR, Russo B, Szczepanek C, Smith CB, Srivastava P, Teplinsky E, Thota R, Traina TA, Zon R, Bourbeau B, Bruinooge SS, Foster S, Grubbs S, Hagerty K, Hurley P, Kamin D, Phillips J, Schenkel C, Schilsky RL, Burris HA 3rd. Pennell NA, et al. Among authors: teplinsky e. J Clin Oncol. 2021 Jan 10;39(2):155-169. doi: 10.1200/JCO.20.02953. Epub 2020 Dec 8. J Clin Oncol. 2021. PMID: 33290128
Mirvetuximab Soravtansine in FRα-Positive, Platinum-Resistant Ovarian Cancer.
Moore KN, Angelergues A, Konecny GE, García Y, Banerjee S, Lorusso D, Lee JY, Moroney JW, Colombo N, Roszak A, Tromp J, Myers T, Lee JW, Beiner M, Cosgrove CM, Cibula D, Martin LP, Sabatier R, Buscema J, Estévez-García P, Coffman L, Nicum S, Duska LR, Pignata S, Gálvez F, Wang Y, Method M, Berkenblit A, Bello Roufai D, Van Gorp T; Gynecologic Oncology Group Partners and the European Network of Gynaecological Oncological Trial Groups. Moore KN, et al. N Engl J Med. 2023 Dec 7;389(23):2162-2174. doi: 10.1056/NEJMoa2309169. N Engl J Med. 2023. PMID: 38055253 Clinical Trial.
Hyperactivated mTOR and JAK2/STAT3 Pathways: Molecular Drivers and Potential Therapeutic Targets of Inflammatory and Invasive Ductal Breast Cancers After Neoadjuvant Chemotherapy.
Jhaveri K, Teplinsky E, Silvera D, Valeta-Magara A, Arju R, Giashuddin S, Sarfraz Y, Alexander M, Darvishian F, Levine PH, Hashmi S, Zolfaghari L, Hoffman HJ, Singh B, Goldberg JD, Hochman T, Formenti S, Esteva FJ, Moran MS, Schneider RJ. Jhaveri K, et al. Among authors: teplinsky e. Clin Breast Cancer. 2016 Apr;16(2):113-22.e1. doi: 10.1016/j.clbc.2015.11.006. Epub 2015 Dec 1. Clin Breast Cancer. 2016. PMID: 26774497 Free PMC article.
19 results